6 March
2024
LungLife AI
Inc
(the
"Company" or "LungLife")
Posting of
Circular
And Notice of Special
Meeting
LungLife AI Inc (AIM: LLAI),
a developer of clinical diagnostic solutions for the early
detection of lung cancer, confirms that
further to the announcements on 4 and 5 March 2024, a Circular in
connection with the Placing and Subscription (the "Circular"), including the Notice of
Special Meeting, has today been despatched to shareholders. A copy
of the Circular and Notice of Special Meeting is available on the
Company's website at
https://lunglifeai.com/investors/shareholder-information/.
The Special Meeting will be held at
11.00 a.m. on 21 March 2024 at Mayer Brown International LLP, at
201 Bishopsgate, London, EC2M 3AF and online by virtual
link.
The Form of Proxy for use in
connection with the Special Meeting should be completed and
returned in accordance with the instructions thereon so as to be
received by the Company's registrars, Link Group, PXS1, Central
Square, 29 Wellington Street, Leeds, LS1 4DL by no later than 11.00
a.m. on 19 March 2024.
The Form of Direction for use in
connection with the Special Meeting should be completed and
returned in accordance with the instructions thereon so as to be
received by the Company's registrars, Link Group, PXS1, Central
Square, 29 Wellington Street, Leeds, LS1 4DL by no later than 11.00
a.m. on 18 March 2024.
Completion of the Form of Proxy or
Form of Direction will not preclude shareholders from attending and
voting in person at the Special Meeting should the so
wish.
The Board believe that each of the
Resolutions is in the best interest of the Company and its
shareholders as a whole and unanimously recommends shareholders to
vote in favour of them, as the Directors have irrevocably
undertaken to do in respect of their own beneficial shareholdings,
which in aggregate represent 0.17 per cent. of the Common Shares
currently in issue.
Unless otherwise defined herein,
capitalised terms used in this announcement shall have the same
meanings as defined in the announcement released by the Company on
4 March 2024.
For further
information please contact:
|
LungLife AI,
Inc.
|
www.lunglifeai.com
|
|
Paul Pagano, CEO
|
Via Walbrook PR
|
|
David Anderson, CFO
|
|
|
|
|
|
Investec Bank plc (Nominated Adviser & Joint
Broker)
|
Tel: +44 (0)20 7597
5970
|
|
Virginia Bull / Cameron MacRitchie / Lydia
Zychowska
|
|
|
|
|
|
Goodbody Stockbrokers UC (Joint Broker)
Tom Nicholson / Cameron Duncan /
William Hall
|
Tel: +44 (0)20 3841
6202
|
|
Walbrook PR Limited
|
Tel: +44 (0)20 7933
8780
|
|
Paul McManus / Alice Woodings /
Phillip Marriage
|
or LungLifeAI@walbrookpr.com
|
About LungLife
LungLife AI is a developer of
clinical diagnostic solutions designed to make a significant impact
in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the
Company's LungLB® test is designed to deliver additional
information to clinicians who are evaluating indeterminate lung
nodules. For more information visit
www.lunglifeai.com